Want to see HK:0858 full AI Analyst Report?
Total Valuation
Extrawell Pharmaceutical Holdings Limited has a market cap or net worth of HK$217.50M. The enterprise value is HK$214.00M.
Market CapHK$217.50M
Enterprise ValueHK$214.00M
Share Statistics
Extrawell Pharmaceutical Holdings Limited has 2,900,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,900,000,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Extrawell Pharmaceutical Holdings Limited’s return on equity (ROE) is -2.61 and return on invested capital (ROIC) is -1.76%.
Return on Equity (ROE)-2.61
Return on Assets (ROA)-1.67
Return on Invested Capital (ROIC)-1.76%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee325.83K
Profits Per Employee-6.20M
Employee Count158
Asset Turnover0.09
Inventory Turnover5.87
Valuation Ratios
The current PE Ratio of Extrawell Pharmaceutical Holdings Limited is ―. Extrawell Pharmaceutical Holdings Limited’s PEG ratio is 0.00038.
PE Ratio―
PS Ratio3.85
PB Ratio0.53
Price to Fair Value0.53
Price to FCF0.00
Price to Operating Cash Flow-209.49
PEG Ratio0.00038
Income Statement
In the last 12 months, Extrawell Pharmaceutical Holdings Limited had revenue of 51.48M and earned -979.71M in profits. Earnings per share was -0.40.
Revenue51.48M
Gross Profit22.75M
Operating Income-9.72M
Pretax Income-986.23M
Net Income-979.71M
EBITDA-1.77M
Earnings Per Share (EPS)-0.40
Cash Flow
In the last 12 months, operating cash flow was -913.00K and capital expenditures 0.00, giving a free cash flow of -913.00K billion.
Operating Cash Flow-913.00K
Free Cash Flow-913.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Extrawell Pharmaceutical Holdings Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.83
52-Week Price Change-40.00%
50-Day Moving Average0.07
200-Day Moving Average0.08
Relative Strength Index (RSI)59.95
Average Volume (3m)2.87M
Important Dates
Extrawell Pharmaceutical Holdings Limited upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).
Last Earnings DateJun 30, 2026
Next Earnings DateNov 27, 2026
Ex-Dividend Date―
Financial Position
Extrawell Pharmaceutical Holdings Limited as a current ratio of 6.04, with Debt / Equity ratio of 45.14%
Current Ratio6.04
Quick Ratio5.92
Debt to Market Cap0.83
Net Debt to EBITDA-33.08
Interest Coverage Ratio-0.37
Taxes
In the past 12 months, Extrawell Pharmaceutical Holdings Limited has paid -8.44M in taxes.
Income Tax-8.44M
Effective Tax Rate<0.01
Enterprise Valuation
Extrawell Pharmaceutical Holdings Limited EV to EBITDA ratio is -144.93, with an EV/FCF ratio of 0.00.
EV to Sales4.99
EV to EBITDA-144.93
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Extrawell Pharmaceutical Holdings Limited has HK$214.16M in cash and marketable securities with HK$169.33M in debt, giving a net cash position of HK$44.83M billion.
Cash & Marketable SecuritiesHK$214.16M
Total DebtHK$169.33M
Net CashHK$44.83M
Net Cash Per ShareHK$0.02
Tangible Book Value Per ShareHK$0.15
Margins
Gross margin is 44.19%, with operating margin of -18.88%, and net profit margin of -1903.05%.
Gross Margin44.19%
Operating Margin-18.88%
Pretax Margin-1915.72%
Net Profit Margin-1903.05%
EBITDA Margin-3.44%
EBIT Margin-18.88%
Analyst Forecast
The average price target for Extrawell Pharmaceutical Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-7.12%
EPS Growth Forecast-523.61%